Free cash flow remains deeply negative with quarterly outflows often exceeding $5 million, forcing the company to prioritize debt servicing—such as the $1.4 million payment in 2026Q1—over essential R&D investment.
| Cash from Operations | -20.54M | -18.2M | -17.95M | -17.09M | -8.8M | -6.94M |
| Operating CF Margin % | - | -7552.28% | -7977.33% | -5408.54% | -3715.19% | -2237.42% |
| Operating CF Growth % | -142.56% | -1.4% | -5.02% | -94.11% | -26.95% | - |
| Net Income | -23.11M | -23.76M | -22.45M | -29.92M | -15.92M | -8.68M |
| Depreciation & Amortization | 314K | 302K | 173K | 133K | 75K | 71K |
| Stock-Based Compensation | 450K | 88K | 0 | 1.57M | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.65M | 3.33M | 4.97M | 12.11M | 7.2M | 1.75M |
| Working Capital Changes | 159K | 1.84M | -638K | -983K | -160K | -82K |
| Change in Receivables | 17K | 765K | -572K | -205K | 47K | -19K |
| Change in Inventory | 96K | 126K | -380K | -10K | -194K | 55K |
| Change in Payables | 155K | 1.39M | -19K | 551K | 342K | 227K |
| Cash from Investing | -173K | -179K | -980K | -153K | -218K | -125K |
| Capital Expenditures | -173K | -179K | -980K | -153K | -218K | -125K |
| CapEx % of Revenue | 73.93% | 74.27% | 435.56% | 48.42% | 91.98% | 40.32% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 40.65M | 16.63M | 20.2M | 21.28M | 8.09M | 8.06M |
| Debt Issued (Net) | 4.1M | 9.07M | 19.08M | 9.44M | 8M | 8M |
| Equity Issued (Net) | 37.22M | 9.44M | 3.56M | 11.85M | 92K | 0 |
| Dividends Paid | -1.96M | -1.82M | -2.45M | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.29M | -62K | 0 | 0 | 0 | 58K |
| Net Change in Cash | 19.94M | -1.74M | 1.26M | 4.04M | 33.16K | 987K |
| Free Cash Flow | -20.71M | -18.38M | -18.93M | -17.24M | -9.02M | -7.06M |
| FCF Margin % | -8850.43% | -7626.56% | -8412.89% | -5456.96% | -3807.17% | -2277.74% |
| FCF Growth % | -25.95% | 2.9% | -9.77% | -91.11% | -27.79% | - |
| FCF per Share | -0.30 | -0.94 | -1.01 | -1.37 | -0.89 | -0.70 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.77x | 0.86x | 0.57x | 0.55x | 0.80x |
| Interest Paid | 7K | 0 | 0 | 26K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
As reported in financial statements, Envoy Medical's operating cash flow consistently trails net income, with the OCF/NI ratio fluctuating significantly, reaching 1.39 in 2026Q1, which suggests that non-cash adjustments and working capital volatility are masking the true extent of the company's underlying cash consumption.
The recurring gap between net income and operating cash flow indicates that the company's accounting losses do not fully capture the cash-intensive nature of its clinical-stage operations. Investors should monitor this divergence, as it suggests that the business model requires substantial cash infusions that are not reflected in standard accrual-based profitability metrics.
Based on recent SEC filings, Envoy Medical's free cash flow remains deeply negative, with quarterly outflows frequently exceeding $5 million, highlighting a structural inability to generate self-sustaining cash flow while the company continues to prioritize long-term regulatory and clinical development over immediate commercial viability.
The consistent negative FCF margins, which reached -155.4% in 2026Q1, underscore the company's reliance on external financing to fund its ongoing operations. This trajectory appears unsustainable without a fundamental shift in revenue generation or a significant reduction in the current burn rate.
According to quarterly data, working capital changes have been highly erratic, including a significant $6.8 million outflow in 2023Q4, which suggests that the company's cash management is subject to unpredictable timing differences in payables and inventory cycles inherent in early-stage medical device manufacturing.
The lack of a stable working capital cycle may indicate difficulties in managing supplier relationships or inventory levels as the company navigates its pre-commercial phase. This volatility warrants further investigation, as it complicates the predictability of the company's cash runway.
As indicated by financial disclosures, Envoy Medical has utilized limited available cash to service debt obligations, such as the $1.4 million payment in 2026Q1, despite the company's critical need for liquidity to fund its ongoing clinical trials and regulatory approval processes.
The allocation of scarce cash toward debt reduction rather than R&D or commercial scaling suggests that management is under pressure to manage leverage, even at the expense of operational growth. This strategy appears to heighten the risk of a liquidity crisis given the company's minimal cash reserves.
Quick answers to the most common questions about buying COCH stock.
Envoy Medical, Inc. (COCH) generated $-18.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Envoy Medical, Inc. (COCH) reported negative free cash flow of $18.4M in 2025, indicating capital requirements exceeded cash from operations.
Envoy Medical, Inc. (COCH) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Envoy Medical, Inc. (COCH) returned $1.8M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.